Scope of nanotechnology in ovarian cancer therapeutics

被引:0
|
作者
Murali M Yallapu
Meena Jaggi
Subhash C Chauhan
机构
[1] Sanford Research/USD,Cancer Biology Research Center
[2] The University of South Dakota,Department of Obstetrics and Gynecology, Sanford School of Medicine
[3] The University of South Dakota,Basic Biomedical Science Division, Sanford School of Medicine
关键词
Ovarian Cancer; Curcumin; Ethylene Oxide; Triblock Copolymer; Polymer Micelle;
D O I
暂无
中图分类号
学科分类号
摘要
This review describes the use of polymer micelle nanotechnology based chemotherapies for ovarian cancer. While various chemotherapeutic agents can be utilized to improve the survival rate of patients with ovarian cancer, their distribution throughout the entire body results in high normal organ toxicity. Polymer micelle nanotechnology aims to improve the therapeutic efficacy of anti-cancer drugs while minimizing the side effects. Herein, different types of polymer micelle technology based nanotherapies such as PLGA, polymerosomes, acid cleavable, thermosensitive, pH sensitive, and cross-linked micelles are introduced and structural differences are explained. Additionally, production methods, stability, sustainability, drug incorporation and drug release profiles of various polymer micelle based nanoformulations are discussed. An important feature of polymer micelle nanotechnology is the small size (10-100 nm) of particles which improves circulation and enables superior accumulation of the therapeutic drugs at the tumor sites. This review provides a comprehensive evaluation of different types of polymer micelles and their implications in ovarian cancer therapeutics.
引用
收藏
相关论文
共 50 条
  • [21] Triptolide: A critical review on antiangiogenesis in cancer and scope in therapeutics
    Ahmed, Naila
    Yafang, Zhang
    JOURNAL OF BIOMIMETICS BIOMATERIALS AND BIOMEDICAL ENGINEERING, 2015, 23 (37-46) : 37 - 46
  • [22] Nanotechnology-Based Cancer Therapeutics—Promise and Challenge—Lessons Learned Through the NCI Alliance for Nanotechnology in Cancer
    Dorothy Farrell
    Krzysztof Ptak
    Nicholas J. Panaro
    Piotr Grodzinski
    Pharmaceutical Research, 2011, 28 : 273 - 278
  • [23] Nanotechnology-Enabled Targeted Protein Degradation for Cancer Therapeutics
    Zhao, Wutong
    Jiang, Yongbin
    Li, Xiufen
    Wang, Hai
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2024, 16 (06)
  • [24] Exploiting Nanotechnology for the Development of MicroRNA-Based Cancer Therapeutics
    Tyagi, Nikhil
    Arora, Sumit
    Deshmukh, Sachin K.
    Singh, Seema
    Marimuthu, Saravanakumar
    Singh, Ajay P.
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2016, 12 (01) : 28 - 42
  • [25] Nanotechnology: going small for a giant leap in cancer diagnostics and therapeutics
    Pierotti, Marco A.
    Lombardo, Claudio
    Rosano, Camillo
    TUMORI, 2008, 94 (02) : 191 - 196
  • [26] MICROTUBULE TARGETS IN CANCER: POTENTIAL OF NANOTECHNOLOGY-BASED THERAPEUTICS
    Kavallaris, Maria
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 19 - 19
  • [27] Novel therapeutics: response and resistance in ovarian cancer
    Zamarin, Dmitriy
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : S16 - S21
  • [28] Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox
    Moufarrij, Sara
    O'Cearbhaill, Roisin E.
    CURRENT ONCOLOGY, 2024, 31 (01) : 97 - 114
  • [29] Emerging peptide therapeutics for the treatment of ovarian cancer
    Veneziani, Ana C.
    Gonzalez-Ochoa, Eduardo
    Oza, Amit M.
    EXPERT OPINION ON EMERGING DRUGS, 2023, 28 (02) : 129 - 144
  • [30] Specific keynote: Molecular therapeutics in ovarian cancer
    Mills, GB
    Fang, XJ
    Lu, YL
    Hasegawa, Y
    Eder, A
    Tanyi, J
    Tabassam, FH
    Mao, ML
    Wang, HW
    Cheng, KW
    Nakayama, Y
    Kuo, WL
    Erickson, J
    Gershenson, D
    Kohn, EC
    Jaffe, R
    Bast, RC
    Gray, J
    GYNECOLOGIC ONCOLOGY, 2003, 88 (01) : S88 - S92